141 related articles for article (PubMed ID: 29970440)
1. Mechanisms of Resistance in Clinical Isolates of
Liu L; Yu J; Tang M; Liu J
Ann Clin Lab Sci; 2018 May; 48(3):355-362. PubMed ID: 29970440
[TBL] [Abstract][Full Text] [Related]
2. Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
Pérez A; Canle D; Latasa C; Poza M; Beceiro A; Tomás Mdel M; Fernández A; Mallo S; Pérez S; Molina F; Villanueva R; Lasa I; Bou G
Antimicrob Agents Chemother; 2007 Sep; 51(9):3247-53. PubMed ID: 17638702
[TBL] [Abstract][Full Text] [Related]
3. soxRS induces colistin hetero-resistance in Enterobacter asburiae and Enterobacter cloacae by regulating the acrAB-tolC efflux pump.
Telke AA; Olaitan AO; Morand S; Rolain JM
J Antimicrob Chemother; 2017 Oct; 72(10):2715-2721. PubMed ID: 29091215
[TBL] [Abstract][Full Text] [Related]
4. Comparative genomics of Enterobacter cloacae complex before and after acquired clinical resistance to Ceftazidime-Avibactam.
Senchyna F; Tamburini FB; Murugesan K; Watz N; Bhatt AS; Banaei N
Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115511. PubMed ID: 34418822
[TBL] [Abstract][Full Text] [Related]
5. Involvement of the AcrAB-TolC efflux pump in the resistance, fitness, and virulence of Enterobacter cloacae.
Pérez A; Poza M; Fernández A; Fernández Mdel C; Mallo S; Merino M; Rumbo-Feal S; Cabral MP; Bou G
Antimicrob Agents Chemother; 2012 Apr; 56(4):2084-90. PubMed ID: 22290971
[TBL] [Abstract][Full Text] [Related]
6. Effect of transcriptional activators SoxS, RobA, and RamA on expression of multidrug efflux pump AcrAB-TolC in Enterobacter cloacae.
Pérez A; Poza M; Aranda J; Latasa C; Medrano FJ; Tomás M; Romero A; Lasa I; Bou G
Antimicrob Agents Chemother; 2012 Dec; 56(12):6256-66. PubMed ID: 23006750
[TBL] [Abstract][Full Text] [Related]
7. Genetic characterization of tigecycline resistance in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes.
Veleba M; De Majumdar S; Hornsey M; Woodford N; Schneiders T
J Antimicrob Chemother; 2013 May; 68(5):1011-8. PubMed ID: 23349441
[TBL] [Abstract][Full Text] [Related]
8. SHV-12 extended spectrum beta-lactamase associated with high-level ceftazidime resistance in Enterobacter cloacae isolated from Thailand.
Tansawai U; Boonkerd N; Polwichai P; Dejsirilert S; Niumsup PR
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):148-54. PubMed ID: 19323047
[TBL] [Abstract][Full Text] [Related]
9. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae.
Keeney D; Ruzin A; Bradford PA
Microb Drug Resist; 2007; 13(1):1-6. PubMed ID: 17536927
[TBL] [Abstract][Full Text] [Related]
10. Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment.
Hornsey M; Ellington MJ; Doumith M; Scott G; Livermore DM; Woodford N
Int J Antimicrob Agents; 2010 May; 35(5):478-81. PubMed ID: 20189357
[TBL] [Abstract][Full Text] [Related]
11. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
Mimoz O; Jacolot A; Padoin C; Tod M; Samii K; Petitjean O
J Antimicrob Chemother; 1998 Mar; 41(3):367-72. PubMed ID: 9578163
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
[TBL] [Abstract][Full Text] [Related]
13. Gene mutations responsible for overexpression of AmpC beta-lactamase in some clinical isolates of Enterobacter cloacae.
Kaneko K; Okamoto R; Nakano R; Kawakami S; Inoue M
J Clin Microbiol; 2005 Jun; 43(6):2955-8. PubMed ID: 15956430
[TBL] [Abstract][Full Text] [Related]
14. Synergistic activity and mechanism of action of ceftazidime and apigenin combination against ceftazidime-resistant Enterobacter cloacae.
Eumkeb G; Chukrathok S
Phytomedicine; 2013 Feb; 20(3-4):262-9. PubMed ID: 23218402
[TBL] [Abstract][Full Text] [Related]
15. Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime.
Shields RK; Iovleva A; Kline EG; Kawai A; McElheny CL; Doi Y
Clin Infect Dis; 2020 Dec; 71(10):2713-2716. PubMed ID: 32236408
[TBL] [Abstract][Full Text] [Related]
16. Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains.
Mimoz O; Jacolot A; Leotard S; Hidri N; Samii K; Nordmann P; Petitjean O
Antimicrob Agents Chemother; 1998 Dec; 42(12):3304-8. PubMed ID: 9835534
[TBL] [Abstract][Full Text] [Related]
17. Decreased quinolone susceptibility in high percentage of Enterobacter cloacae clinical isolates caused only by Qnr determinants.
Zhao X; Xu X; Zhu D; Ye X; Wang M
Diagn Microbiol Infect Dis; 2010 May; 67(1):110-3. PubMed ID: 20227223
[TBL] [Abstract][Full Text] [Related]
18. [Resistance to cefepime in Enterobacter cloacae isolates from hospitals in Bogotá, Colombia].
González-Mejía EB; Valenzuela EM; Mantilla-Anaya JR; Leal-Castro AL; Saavedra-Trujillo CH; Eslava-Schmalbach J; Sierra-Rodriguez P
Rev Salud Publica (Bogota); 2006; 8(2):191-9. PubMed ID: 17191603
[TBL] [Abstract][Full Text] [Related]
19. What does the susceptible-dose dependent interpretive category for cefepime in ESBL-producing bacteria?
Menegucci TC; Bastos MS; Viana GF; Moreira RRB; Garcia LB; Cardoso CL; Tognim MCB
J Chemother; 2017 Jun; 29(3):189-194. PubMed ID: 27077929
[TBL] [Abstract][Full Text] [Related]
20. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?
Hilty M; Sendi P; Seiffert SN; Droz S; Perreten V; Hujer AM; Bonomo RA; Mühlemann K; Endimiani A
Int J Antimicrob Agents; 2013 Mar; 41(3):236-49. PubMed ID: 23313399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
